Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma

Bone Marrow Transplantation

Volumn 30, Issue 12, 2002, Pages 805-812

  Nelson Jr , R P ^a   Logan, T F ^a   Abonour, R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hematopoietic cell transplantation; Nonmyeloablative; Renal cell carcinoma

Indexed keywords

ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERFERON; INTERLEUKIN 2; MELPHALAN; RECOMBINANT CYTOKINE; THALIDOMIDE; THIOTEPA;

ALLOTRANSPLANTATION; CANCER REGRESSION; CAPILLARY LEAK SYNDROME; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOKINES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; MELPHALAN; MULTICENTER STUDIES; NEPHRECTOMY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE;

EID: 0036947850     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703740     Document Type: Review

References (101)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. New Engl J Med 1996; 335: 865-875.
2. Linehan WM, Zbar B, Bates SE et al. Cancer of the kidney and ureter. In: VT DeVita Jr, S Hellman, SA Rosenburg (eds). Cancer: Principles and Practice of Oncology, 6th edn, Lippincott Williams and Wilkins: Philadelphia, PA, 2001, pp 1362-1398.
3. Montie JE, Stewart BH, Straffon RA et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 117: 272-275.
4. Gleave ME, Elhilali M, Fradet Y et al. Interferon gamm-Ib compared with placebo in metastatic renal cell carcinoma. New Engl J Med 1998; 338: 1265-1271.
5. Motzer RJ, Mazumdar M, Bacik J et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928-1935.
6. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin N Am 1993; 20: 303-321.
7. Logan TF, Trump DL. The role of cytotoxic chemotherapy in the management of renal cancer. In: MS Ernstoff, JA Heaney, RE Peschel (eds). Urologic Cancer. Blackwell Science: Cambridge, 1997, 444-463.
8. Pastore RD, Pfeffer LM, Nanus DM. Renal cell carcinoma and interferon at the millennium. Cancer Invest, 2001; 19: 281-291.
9. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New Engl J Med 2001; 345: 1655-1659.
10. Motzer RJ, Schwatrz L, Law TM et al. Interferon alpha 2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13: 1950-1957.
11. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980.
12. Atzpodien J, Kirchner H, Hanninen EL et al. Interleukin-2 in combination with interferon- and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A: S6-S8.
13. Yang JC-Y. Interleukin-2: clinical applications. Renal cell carcinoma. In: Rosenburg SA (ed.). Principles and Practice of the Biologic Therapy of Cancer, third edn, Lippincott, Williams and Wilkins: Philadelphia, 2000, pp. 73-82.
14. Schwartzentruber DJ. Biologic therapy with Interleukin-2: clinical applications. In: VT DeVita Jr, S Hellman, SA Rosenberg (eds). Biologic Therapy of Cancer, second edn. JB Lippincott, Philadelphia, 1995, pp. 235-249.
15. Dutcher JP, Logan T, Gordon M et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000; 6: 3442-3450.
16. Rosenberg SA, Yang JC, Topalian SL et al. The treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271: 907-913.
17. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696.
18. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(Suppl. 1): S55-S57.
19. Sleijfer DTH, Janssen RAJ, Butler J. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992; 10: 1119-1123.
20. Yang JC, Topalian SL, Parkinson D et al. A randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994; 12: 1572-1576.
21. McDermott D, Flaherty L, Clark J et al. A randomized phase III trial of high-dose Interleukin-2 (HD IL-2) versus subcutaneous (SC) IL-2/Interferon (IFN) in patients with metastatic renal cell carcinoma (RCC). Proc ASCO 2001; 20: 172a.
22. Finke JH, Rayman P, Hart L et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J Immunother Emphasis Tumor Immunol 1994; 15: 91-104.
23. Alexander JP, Kudoh S, Melsop KA et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993; 53: 1380-1387.
24. Gaugler B, Brouwenstijn N, Vantomme V et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996; 44: 323-330.
25. Brouwenstijn N, Gaugler B, Kruse KM et al. Renal cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int J Cancer 1996; 68: 177-182.
26. Bernhard H, Maurer MJ, Jager E et al. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma. Scand J Immunol 1996; 44: 285-292.
27. Caignard A, Guillard M, Gaudin C et al. In situ demonstration of renal cell carcinoma-specific T-cell clones. Int J Cancer 1996; 66: 564-570.
28. Bain C, Merrouche Y, Puisieux I et al. B7.1 gene transduction of human renal cell carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int J Cancer 1996; 67: 769-776.
29. Wang YC, Lihue Z, McHugh R et al. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation. J Immunother 1996; 19: 1-8.
30. Schendel DJ, Oberneder R, Falk CS et al. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med 1997; 75: 400-413.
31. + selected tumor-infiltrating lymphocytes from primary tumors. J Urol 1997; 158: 740-745.
32. Topalian SL, Solomon D, Avis FP et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988; 6: 839-853.
33. Kradin RL, Kurnick JT, Lazurus DS et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989; 1: 577-580.
34. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, phase III trial of CD8 (+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17: 2521-2529.
35. Chang AE, Yoshizawa H, Sakai K et al. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 1993; 53: 1043-1050.
36. Chang AE, Aruga A, Cameron M et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997; 15: 796-807.
37. Logan T, Kirkwood J, Wolmark N et al. Pilot study of in vitro sensitized (IVS) T cells in adoptive transfer therapy of cancer. Proc ASCO 1990; 9: Abstr. 726, 188.
38. Weidman E, Logan T, Yasumura S et al. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res 1993; 53: 4745-4749.
39. Logan T, Banner B, Ernstoff M et al. Inflammatory cell infiltrate in a responding metastatic nodule after adoptive transfer of in vitro sensitized T cells and systemic interleukin-2. Clin Exp Immunol 1998; 114: 347-354.
40. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 1997; 226: 1-5.
41. Weber J, Schulz W. Clinical trials of dendritic cells for cancer. Prin Prac Bio Ther Cancer Updates 2000; 1: 1-12.
42. Zitvogel L, Mayardomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1-associated cytokines. J Exp Med 1996; 183: 87-97.
43. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphomas using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-58.
44. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 1999; 93: 2411-2419.
45. Murphy GP, Tjoa BA, Simmons SJ et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostrate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38: 73-78.
46. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
47. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332-336.
48. Storb R, Prentice RL, Hansen JA, Thomas ED. Association between HLA-B antigens and acute graft-versus-host disease. Lancet 1983; 2: 816-819.
49. Kersey JH, Meuwissen HJ, Yunis EJ, Good RA. Graft-versus-host reactions following transplantation of allogeneic hematopoietic cells. Hum Pathol 1971; 2: 389-402.
50. Bortin MM, Rimm AA, Saltzstein EC. Graft-versus-leukemia: quantification of adoptive immunotherapy in murine leukemia. Science 1973; 179: 811-813.
51. Odom L, August C, Githen J. Remission of relapsed leukemia during graft-versus-host reaction. Lancet 1978; 2: 537-540.
52. Weiden PL, Flourney N, Thomas ED et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow graft. New Engl J Med 1979; 300: 1068-1073.
53. Weisdorf DJ, Nesbit ME, Ramsey NK et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. J Clin Oncol 1987; 5: 1348-1355.
54. Higano CS, Brixey M, Bryant EM et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990; 50: 175-177.
55. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
56. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
57. Rondon G, Giralt S, Huh Y. Graft-versus-effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669-672.
58. van Besien K, de Lima M, Giralt S et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977-982.
59. Sykes M, Eisenthal A, Sachs DH. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. J Immunol 1988; 140: 2903-2911.
60. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 2391-2396.
61. Sykes M, Bukhari Z, Sachs DH. Graft versus leukemia effect using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4: 465-474.
62. Pelot MR, Person DA, Swenson K et al. Lymphopoietic graft-versus-host reactions can be induced without graft-versus-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133-143.
63. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1995; 89: 3048-3054.
64. Huss R, Deeg HJ, Gooley T et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996; 18: 767-776.
65. Walters MC, Patience M, Leisenring W et al. Bone marrow transplantation for sickle cell disease. New Engl J Med 1996; 335: 369-376.
66. Andreani M, Manna M, Lucarelli G et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87: 3494-3499.
67. Kapelushmik J, Or R, Filon D et al. Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. Blood 1995; 86: 3241-3246.
68. Weinberg RS, Vlachos A, Najfeld V et al. Disparate lymphoerythroid donor to recipient chimerism in a beta-thalassaemia bone marrow transplant recipient with red cell indices indicative of apparent full engraftment. Br J Haematol 1997; 99: 61-63.
69. Buckley RH, Schiff SE, Schiff RI et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. New Engl J Med 1999; 340: 508-516.
70. Petz LD, Ulm P, Wallace RB et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood 1987; 70: 1331-1337.
71. Lokhorst H, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
72. Porter DL, Roth MS, McGarigle C. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-104.
73. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2220.
74. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
75. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
76. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
77. Storb R. Nonmyeloablative preparative regimens: experimental data and clinical practice. In: Perry MC (ed.). American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology: Alexandria, VA, 1999, pp. 241-246.
78. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480-484.
79. Childs R, Bahceci E, Clave E et al. Non-myeloablative allogeneic peripheral blood stem cell transplants (PBSCT) for malignant diseases reduces transplant-related mortality (TRM). Blood 1998; 92 (Suppl. 1): 137a.
80. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precede alloimmune responses. Blood 1999; 94: 3234-3241.
81. Champlin R, Khouri I, Anderlini P et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2001; 27 (Suppl. 2): S13-S22.
82. Giralt S, Slavin SE (eds). Non-myeloablative Stem Cell Transplantation (NST) Darwin Scientific Publishing: Abingdon. 2000.
83. Champlin R, Khouri I, Kornblau S et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999; 11: 87-95.
84. Feinstein L, Storb R. Nonmyeloablative hematopoietic cell transplantation. Curr Opin Oncol 2001; 13: 95-100.
85. Storb R. Nonmyeloalbative preparative regimens: how relevant for acute myelogenous leukemia. Leukemia 2001; 15: 662-663.
86. Amado RG, Schiller GJ. Nonmyeloablative approaches to the treatment of sickle hemaglobinapathies. Semin Oncol 2000; 27 (Suppl. 2): 82-89.
87. Graber C, de Almeider KN, Childs R et al. CMV reactivation in nonmyeloablative HSCT. Bone Marrow Transplant 2001; 27: 775.
88. Spitzer TR. Nonmyeloablative allogeneic stem cell transplants strategies and mixed chimerism. Oncologist 2000; 5: 215-223.
89. Slavin S. New strategies for bone marrow transplantation. Curr Opin Immunol 2000; 12: 542-551.
90. Childs RW. Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases. Cancer J Sci Am 2000; 6: 179-187.
91. Jursic JG, Cathcart K, Pinella-Ibarz J et al. Advances in immunotherapy of hematological malignancies: cellular and humoral approaches. Curr Opin Hematol 2000; 7: 247-254.
92. Margolis J, Borrello I, Flinn IW. New approaches to treating malignancies with stem cell transplantation. Semin Oncol 2000; 27: 524-530.
93. Barrett AJ. Conditioning regimens for allogeneic stem cell transplants. Curr Opin Hematol 2000; 7: 339-342.
94. Childs R, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral blood progeniton cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044-2049.
95. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. New Engl J Med 2000; 343: 750-758.
96. Pedrazzoli P, Da Prada GA, Giorgiani G et al. Allogeneic blood stem cell transplantation after a reduced-intensity preparative regimen. Cancer 2002; 84: 2409-2415.
97. Rini BI, Zimmerman T, Stadler WM et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment and clinical results. J Clin Oncol 2002; 20: 2017-2024.
98. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
99. Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 1994; 57: 82-87.
100. Sandmaier BM, Masgood N, Thompson JA, Storb R. Fludarabine and total body radiation (TBI) followed by allogeneic hematopoietic stem cell transplant (HSCT) as immunotherapy for metastatic renal cell carcinoma (MRCC). Proc ASCO 2002; 420a, (Abstr. 1677).
101. Ueno NT, Cheng YC, Giralt SA et al. Complete donor chimerism by fludarabine/melphalan in mini-allogeneic transplantation for metastatic renal cell carcinoma (RCC) and breast cancer (BC). Proc ASCO 2002: 415a (Abstr. 1659).